Several other analysts have also issued reports on the stock. HC Wainwright decreased their price target on shares of TG Therapeutics from $68.00 to $19.00 and set a buy rating on the stock in a research report on Monday, April 18th. Cantor Fitzgerald restated an overweight rating on shares of TG Therapeutics in a research report on Monday, May 9th. B. Riley decreased their price target on shares of TG Therapeutics from $23.00 to $17.00 and set a buy rating on the stock in a research report on Monday, June 13th. Finally, Bank of America started coverage on shares of TG Therapeutics in a research report on Friday, May 20th. They issued an underperform rating on the stock. Three analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Hold and an average price target of $21.25.
NASDAQ:TGTX opened at $4.04 on Friday. TG Therapeutics has a 1 year low of $3.48 and a 1 year high of $41.00. The firm’s fifty day simple moving average is $6.12 and its 200 day simple moving average is $10.58. The company has a current ratio of 4.43, a quick ratio of 4.43 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $583.52 million, a PE ratio of -1.65 and a beta of 2.28.
Hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp grew its position in shares of TG Therapeutics by 65.3% during the 1st quarter. State Street Corp now owns 9,628,584 shares of the biopharmaceutical company’s stock worth $91,568,000 after buying an additional 3,804,406 shares during the period. Maverick Capital Ltd. grew its position in shares of TG Therapeutics by 83.1% during the 4th quarter. Maverick Capital Ltd. now owns 6,034,875 shares of the biopharmaceutical company’s stock worth $114,663,000 after buying an additional 2,738,424 shares during the period. Norges Bank acquired a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $19,436,000. Federated Hermes Inc. acquired a new position in TG Therapeutics during the first quarter valued at approximately $7,442,000. Finally, Invesco Ltd. grew its holdings in TG Therapeutics by 60.4% during the third quarter. Invesco Ltd. now owns 1,798,393 shares of the biopharmaceutical company’s stock valued at $59,849,000 after purchasing an additional 677,100 shares during the period. 70.52% of the stock is owned by institutional investors.
TG Therapeutics Company Profile (Get Rating)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.
- Get a free copy of the StockNews.com research report on TG Therapeutics (TGTX)
- Ride Out The Recession With These Dividend Kings
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.